Find disease awareness content and relevant supporting materials
Evaluate Reversal of Pathological Epidermal Phenotype in Severe Atopic Dermatitis (AD) With Suppression of Immune Activation During Cyclosporine A Therapy
Atopic Dermatitis (AD) or eczema is a chronic relapsing inflammatory disease that affects 1-3% of the adults and up to...
Positive Dupixent phase III data in children aged 6 months to 5 years with moderate to severe atopic dermatitis is published in The Lancet
Regeneron Pharmaceuticals, Inc and Sanofi announced that The Lancet has published positive results from a Phase III Dupixent (dupilumab) trial in children aged 6 months to 5 years with uncontrolled moderate-to-severe atopic dermatitis
Biological therapies for atopic dermatitis: An update.
Severe atopic dermatitis, which affects both adults and children, is a debilitating disorder with a significant decline of patients' quality of life. Although aetiopathogenic factors are currently a topic of study and interpretation...
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
Objective: This placebo-controlled, double-blind trial (NCT01979016) evaluated the efficacy, safety, and effects of dupilumab on molecular/cellular lesional and nonlesional skin phenotypes and systemic type 2 biomarkers...
CHMP recommends approval for Adtralza in moderate-to-severe atopic dermatitis
LEO Pharma announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending to extend the approval of Adtralza (tralokinumab) in the European Union (EU) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy